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for peptic ulcer associated with anti-platelet therapy used alone or in combination 
with PPI by patients previously diagnosed with peptic ulcers. In total, 14,627 patients 
(aspirin [12,001] and clopidogrel [2,626]) who had history of peptic ulcer before
he or she began using antiplatelet agent were selected. Recurrence of peptic ulcer 
were analyzed using Cox proportional hazards model, with adjustment for age, 
gender, medical history, using of non-steroidal anti-inﬂ ammatory drugs, and other 
medications. Propensity score method was used in adjustment for self selection 
bias. RESULTS: The incidences of recurring peptic ulcer per person years were
0.125 for Aspirin without PPI, 0.102 for Aspirin with PPI, 0.128 for Clopidogrel
without PPI, and 0.152 for Clopidogrel with PPI. Patients taking clopidogrel were 
at signiﬁ cantly lower risk of hospitalization for peptic ulcer (HR 0.85 [95% CI: 
0.76–0.95]) than those taking aspirin. Concomitant use of PPI signiﬁ cantly lowered 
that risk for aspirin users (0.76 [0.64–0.91]), but did not appear to offer the same 
protection to clopidogrel users (1.08 [0.89–1.33]). An adjusted survival curve of risk 
of recurring peptic ulcer showed that the risk increased signiﬁ cantly faster in clopido-
grel users than patients using aspirin and PPI, though their average drug cost per 
person year was NT $12,500.08 o 15,134.46, which was much higher than NT
$3,712.39 o 14,608.05 spent by Aspirin-PPI users. CONCLUSIONS: Aspirin plus a
PPI could be considered more cost-effective to clopidogrel in reducing risk of peptic
ulcer, when used for the secondary prevention of cardiovascular events in high gas-
trointestinal risk group.
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OBJECTIVES: To examine Thai Civil Servant Medical Beneﬁ t Scheme (CSMBS) 
beneﬁ ciaries’ preferences for attributes of drug beneﬁ t plans. METHODS: Based on
conjoint analysis, a self-administered questionnaire was designed to include ten hypo-
thetical drug beneﬁ t plans which were described by four attributes e.g. patient cost 
sharing, formulary restrictiveness, quantity restrictiveness, and accessibility restrictive-
ness. Each attribute contained various levels. A total of 600 questionnaires were placed 
at various governmental ofﬁ ces in a province of southern Thailand. The respondents
were asked to evaluate and determine overall preference for each plan. Part-worth 
utility values for each level of each attribute for each beneﬁ ciary were estimated. 
Importance scores for each attribute were calculated and averaged across all the ben-
eﬁ ciaries. A segmentation analysis was also analyzed from the results of conjoint
analysis. RESULTS: Response rate was about 66%. Average age of the respondents
was about 43 years old. Most of them were female (60.6%) and married (69.9%). 
More than 80% of them had either a bachelor degree or higher. Their average monthly
income was about 22,832 Baht. The estimated relative importance from a conjoint 
analysis indicated that the cost sharing was the most important attributes (44.95%
relative importance). Among the levels of cost sharing attribute, coinsurance at 25% 
was the most preferred choice. Formulary restrictiveness was the second most impor-
tant attribute (25.54% relative importance), while the restrictions of accessibility and
quantity had similar relative importance for the beneﬁ ciaries. The results from market
segmentation analysis showed that almost half of the respondents considered cost
sharing as the most important attribute for their preferred plan. CONCLUSIONS:
This study demonstrated the CSMBS beneﬁ ciaries’ preferences for the attributes of 
drug beneﬁ t schemes. Among four studied attributes, the most important attribute
that the respondents chose was cost sharing.
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OBJECTIVES: The increase in premium-priced orphan drugs coupled with health care
budget constraints will pressure managed care plans to consider restricting market 
access. Coverage and reimbursement of the top ten selling FDA-designated orphan 
drugs (alglucerase, imiglucerase, imatinib, adalimumab, lamotrignine, lidocaine patch,
modaﬁ nil, cinacalcet, buprenorphine/naloxone, topiramate) were analyzed for seven 
of the most populous Medicare managed care plans (Aetna, SilverScript, Coventry,
Medco, Cigna, United HealthCare, Humana). METHODS: The formulary tier struc-
ture, out-of-pocket costs (OPC) and utilization restrictions (UR)—pre-authorization
(PA), quantity limits (QL) and step therapy (ST)—were obtained from CMS (www.
medicare.gov). Orphan drugs analyzed were the top ten in 2007 retail sales (SDI
VONA). OPC was reported as a percentage of the drugs’ costs paid by patients, 
determined by averaging initial, gap, and catastrophic coverage levels. RESULTS:
Among the seven plans covering the ten drugs, PA was the most common UR (40.0%), 
followed by QL (35.7%) and ST (2.9%). Alglucerase, the 3rd most expensive drug, 
had the highest OPC (59.9%) on average among all seven plans. Modaﬁ nil, the 4th 
least expensive, had the lowest OPC (40.3%) on average. However, modaﬁ nil was
subjected to utilization restrictions by all plans studied and most frequently overall 
(13 of 21 possible restrictions; 61.9% OPC) while alglucerase, lamotrignine (3rd least 
expensive), buprenorphine/naloxone (5th least expensive) were the least frequently
restricted (14.3% each). Medco had the highest OPC for the ten drugs (52.9%) while 
SilverScript had the lowest (40.1%). Coventry employed URs most frequently (53.3%)
while SilverScript used them least frequently (6.7%). CONCLUSIONS: Orphan drugs 
do not appear to be immune to market access limitations. URs on orphan drugs were
prevalent in the most populous plans, with patients bearing 40–60% of the drugs’ 
costs out-of-pocket. The extent of restrictions was not proportional to the drugs’ price,
suggesting that more research is warranted to investigate myriad factors related to 
orphan drug access.
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OBJECTIVES: Hospital formularies are variously viewed as tools for enhancing 
patient safety by promoting more rational prescribing to obtrusive cost barriers that 
negatively affect patient care. The objective of this study was to describe the develop-
ment of a measure for assessing clinical practitioners’ knowledge, attitudes and behav-
iors with respect to the formulary process and committee. METHODS: The Formulary 
Culture Survey (FCS) was modeled on the established literature of patient safety 
culture measurement. Focus group interviews of formulary committee members identi-
ﬁ ed speciﬁ c themes for item development within ﬁ ve conceptualized domains: (1)
Global Trust, Conﬁ dence and Credibility, (2) Structure and Process of Formulary 
Committee, (3) Dimensions of Formulary Performance, (4) General Attitudes, (5) 
Familiarity of Drug Information Resources. Items were pilot tested in a 50 question 
online survey. These items were then categorized according to expert judgment into 
14 domains. Reﬁ nement to the FCS was guided by factor analysis and Rasch models. 
RESULTS: Attending and resident physicians from a university (n  54) and county 
hospital (n  135) completed the initial survey. The 50 items indicated 14 separate
underlying constructs. Exploratory factor analysis supported 4 domains that accounted 
for 39% of the variance in the responses: Physician Attitudes Towards Formulary
(General), Trust in Formulary Committee Decisions, Beliefs About Formulary
Approval Process and Physician Attitudes Towards Pharmaceutical Industry Inﬂ uence. 
Based on Rasch and factor analysis, 12 items were identiﬁ ed for modiﬁ cation in future 
versions. CONCLUSION: Preliminary evidence supports the conceptual basis for a 
tool to measure formulary culture. The identiﬁ cation, operationalization and valida-
tion of the constructs that comprise the knowledge, attitudes and behaviors of clinical 
practitioners with respect to drug formularies may provide insight into the perceived 
role of formularies in promoting good clinical outcomes. Future research involves a 
larger scale validation study.
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OBJECTIVES: As the US reimbursement landscape becomes increasingly restrictive,
we hypothesized that health technology appraisals (HTAs) published by the National 
Institute for Clinical Excellence (NICE; UK) would inﬂ uence drug prescribing 
and expenditures in the US. The primary objective was to determine whether HTAs 
have impacted trends in prescription volume (TRx), average retail price (ARP) and 
out-of-pocket costs (OPC) of 11 drugs covered in recent HTAs. METHODS: Six 
NICE HTAs published since 2007, evaluating a total of 11 non-injectable drugs, were
analyzed, of which three freely advocated use of the drugs studied, two encouraged
use for restricted populations and one discouraged utilization. TRx, ARP and OPC 
were collected monthly for the same duration pre- and post-HTA until November 
2008. Parameters were collected using SDI’s VONA and VOPA databases. Statistical
analyses were performed using one-way ANOVA; statistically signiﬁ cant results had
p  0.05. RESULTS: A NICE appraisal supporting the use of four Alzheimer’s drugs
(donepezil, galantamine, rivastigmine, memantine) was associated with signiﬁ cant 
increases in TRx, ARP and a nearly signiﬁ cant increase in OPC (p  0.07). There was 
a signiﬁ cant decrease in OPC of hepatitis B drug, entecavir, correlated with an HTA
supporting its use in addition to a discouraging guidance of its competitor, telbivudine.
Guidance restricting the population and duration to receive hyperparathyroidism 
drug, cinacalcet, was associated with signiﬁ cant increases in TRx, ARP and OPC. An 
HTA cautiously highlighting the success of opioid-abstinence drug, naltrexone, in 
counseled patients correlated with signiﬁ cant increases in all three market metrics. 
CONCLUSIONS: NICE HTAs decisions appear to be associated with mixed effects 
on prescription utilization and expenditures in the US. The inﬂ uence of NICE decisions 
on the US market should be monitored as HTAs are expected to play a more signiﬁ cant
role in a more judicious reimbursement environment, in which payers increasingly
seek evidence to support formulary decisions.
